Attached files
| file | filename |
|---|---|
| 10-K/A - SensiVida Medical Technologies, Inc. | v210956_10ka.htm |
| EX-3.1 - SensiVida Medical Technologies, Inc. | v210956_ex3-1.htm |
| EX-31.2 - SensiVida Medical Technologies, Inc. | v210956_ex31-2.htm |
| EX-32.1 - SensiVida Medical Technologies, Inc. | v210956_ex32-1.htm |
| EX-31.1 - SensiVida Medical Technologies, Inc. | v210956_ex31-1.htm |
| EX-10.15 - SensiVida Medical Technologies, Inc. | v210956_ex10-15.htm |
| EX-10.16 - SensiVida Medical Technologies, Inc. | v210956_ex10-16.htm |
| EX-10.13 - SensiVida Medical Technologies, Inc. | v210956_ex10-13.htm |
| EX-10.14 - SensiVida Medical Technologies, Inc. | v210956_ex10-14.htm |
FIRST LICENSE AGREEMENT
AMENDMENT
THE FIRST LICENSE AGREEMENT AMENDMENT
is made as of April 20, 2010 by ROCHESTER BIOVENTURE CENTER, INC., ("Licensor"),
and SENSIVIDA MEDICAL TECHNOLOGIES, INC. ("Licensee").
WITNESSETH:
WHEREAS, Licensor has provided to
Licensee for use of Room 164 located at 77 Ridgeland Road, Henrietta, New York
14623 pursuant to the terms of a certain LICENSEE AGREEMENT, dated December 15,
2008 by and between Licensor and Licensee (the "License Agreement");
and
WHEREAS, Licensor and Licensee desire
to amend the terms of the License Agreement to include Office 101D as part of
the Premises pursuant to the terms of this First License Agreement
Amendment;
NOW, THEREFORE, in consideration of Ten
Dollars ($10.00) in hand paid and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto do
hereby agree as follows:
1. The
Premises is hereby amended to be Room 164 and Office 101D located at 77
Ridgeland Road, Henrietta, NY 14623.
2. The
annual License Fee for Room 164 and Office 101D shall be $13,200.00, to be paid
in monthly installments of $1,100.00.
3. Licensor
agrees that Licensee has the option to extend the term of the License to
month-to-month tenancy subject to all covenants, conditions and terms of the
current License Agreement. The License shall run month-to-month
effective May 1, 2010 until either party notifies the other of its intention to
terminate the License, and in such event, the License will expire on the last
day of the next month after delivery of said notice.
4. Each
party warrants and represents to the other party hereto that it has not dealt
with any brokers in connection with this First License Agreement
Amendment. Each party hereby indemnifies and holds the other party
harmless from any and all loss and expense arising out of or in connection with
any breach of the foregoing warranty and representation. The
provisions of this paragraph 2 shall survive the expiration or earlier
termination of the Agreement.
5. This
First License Agreement Amendment shall commence on May 1, 2010 and will
terminate as provided in paragraph 3 above, or on February 13, 2013, whichever
occurs earlier.
6. All
capitalized terms used herein and not otherwise defined shall have the meanings
ascribed thereto in the License Agreement. Except as herein expressly
amended, the License Agreement shall remain unchanged and is hereby ratified
confirmed and approved.
IN
WITNESS WHEREOF Licensor and Licensee have executed this License Agreement
Amendment as of the day and year first above written.
|
LICENSOR:
|
LICENSEE:
|
|||
|
ROCHESTER
BIOVENTURE CENTER, INC.
|
SENSIVIDA
MEDICAL TECHNOLOGIES, INC.
|
|||
|
By:
|
/s/ James S. Senall
|
By:
|
/s/ Jose Mir
|
|
|
Name: James
S. Senall
|
Name: Jose
Mir
|
|||
|
Title: President
|
Title: President
and CEO
|
|||